Ribavirin monotherapy in oral cancers reduced phospho-eIF4E levels in 4/6 patients but provided limited therapeutic benefit, with the best outcomes being stable disease lasting up to ~7 months [142] suggesting eIF4E inhibition may be best in combination. The gene discussed is EIF4E; the disease is lip and oral cavity carcinoma.